A short guide to electrophysiology and ion channels

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 20, Issue 1, 2017, Pages 48-67

  Rubaiy, Hussein Nori ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ION CHANNEL;

ARTICLE; CELL MEMBRANE; ELECTROPHYSIOLOGICAL PROCEDURES; ELECTROPHYSIOLOGY; HEART MUSCLE EXCITABILITY; HUMAN; ION CURRENT; NERVE MEMBRANE; NEUROLOGIC DISEASE; NEUROSCIENCE; PATCH CLAMP TECHNIQUE; PATHOPHYSIOLOGY; PHARMACOLOGY; ANIMAL; METABOLISM;

ANIMALS; ELECTROPHYSIOLOGY; HUMANS; ION CHANNELS; NERVOUS SYSTEM DISEASES; PATCH-CLAMP TECHNIQUES;

EID: 85015811495     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j32p6r     Document Type: Article

References (130)

1. Piccolino M. Animal electricity and the birth of electrophysiology: the legacy of Luigi Galvani. Brain Res Bull. 1998; 46(5): 381-407.
2. Piccolino M. Luigi Galvani and animal electricity: two centuries after the foundation of electrophysiology. Trends Neurosci. 1997; 20(10): 443-8.
3. Bresadola M. Medicine and science in the life of Luigi Galvani (1737-1798). Brain Res Bull. 1998; 46(5): 367-80.
4. Finkelstein G. Mechanical neuroscience: Emil du Bois-Reymond’s innovations in theory and practice. Front Syst Neurosci. 2015; 9: 133.
5. Seyfarth EA. Julius Bernstein (1839-1917): pioneer neurobiologist and biophysicist. Biol Cybern. 2006; 94(1): 2-8.
6. Hille B. Ion Channels of Excitable Membranes. third edn ed: Sunderland, Sinauer Associates; 2001.
7. Hodgkin AL, Huxley AF. Movement of sodium and potassium ions during nervous activity. Cold Spring Harbor symposia on quantitative biology. 1952; 17: 43-52.
8. Neher E, Sakmann B, Steinbach JH. The extracellular patch clamp: a method for resolving currents through individual open channels in biological membranes. Pflugers Arch. 1978; 375(2): 219-28.
9. Aidley DJ, Stanfield, P. R. Ion channels: Molecules in action;. 1st ed ed. New York: Cambridge University Press; 1996.
10. Rubaiy HN, Linsdell P. Location of a permeant anion binding site in the cystic fibrosis transmembrane conductance regulator chloride channel pore. J Physiol Sci. 2015; 65(3): 233-41.
11. Lodwick D, Rainbow RD, Rubaiy HN, Al Johi M, Vuister GW, Norman RI. Sulfonylurea receptors regulate the channel pore in ATPsensitive potassium channels via an intersubunit salt bridge. Biochem J. 2014; 464(3): 343-54.
12. Linley JE. Perforated whole-cell patch-clamp recording. Methods in molecular biology. 2013; 998: 149-57.
13. Naylor J, Minard A, Gaunt HJ, Amer MS, Wilson LA, Migliore M, et al. Natural and synthetic flavonoid modulation of TRPC5 channels. Br J Pharmacol. 2016; 173(3): 562-74.
14. Ludlow MJ, Gaunt HJ, Rubaiy HN, Musialowski KE, Blythe NM, Vasudev NS, et al. (-)-Englerin A-evoked Cytotoxicity is Mediated by Na+ Influx and Counteracted by Na+/K+-ATPase. The Journal of biological chemistry. 2016.
15. Goldin AL. Expression of Ion Channels in Xenopus Oocytes. Expression and Analysis of Recombinant Ion Channels: From Structural Studies to Pharmacological Screening. 2006.
16. Rubaiy HN. The therapeutic agents that target ATP-sensitive potassium channels. Acta Pharm. 2016; 66(1): 23-34.
17. Fejtl M, Czubayko U, Hummer A, Krauter T, Lepple-Wienhues A. Flip-the-tip: automated patch clamping based on glass electrodes. Methods in molecular biology. 2007; 403: 71-85.
18. Yajuan X, Xin L, Zhiyuan L. A comparison of the performance and application differences between manual and automated patch-clamp techniques. Current chemical genomics. 2012; 6: 87-92.
19. Dunlop J, Bowlby M, Peri R, Vasilyev D, Arias R. High-throughput electrophysiology: an emerging paradigm for ion-channel screening and physiology. Nat Rev Drug Discov. 2008; 7(4): 358-68.
20. Farre C, Stoelzle S, Haarmann C, George M, Bruggemann A, Fertig N. Automated ion channel screening: patch clamping made easy. Expert Opin Ther Targets. 2007; 11(4): 557-65.
21. Priest BT, Swensen AM, McManus OB. Automated electrophysiology in drug discovery. Current pharmaceutical design. 2007; 13(23): 2325-37.
22. Lu Q, An WF. Impact of novel screening technologies on ion channel drug discovery. Combinatorial chemistry & high throughput screening. 2008; 11(3): 185-94.
23. Dabrowski MA, Dekermendjian K, Lund PE, Krupp JJ, Sinclair J, Larsson O. Ion channel screening technology. CNS & neurological disorders drug targets. 2008; 7(2): 122-8.
24. Xu H, Martinoia E, Szabo I. Organellar channels and transporters. Cell Calcium. 2015; 58(1): 1-10.
25. Bezanilla F. Ion channels: from conductance to structure. Neuron. 2008; 60(3): 456-68.
26. Aidley DJ, Stanfield PR. Ion channels: molecules in action: Cambridge University Press; 1996.
27. Lee A, Fakler B, Kaczmarek LK, Isom LL. More than a pore: ion channel signaling complexes. J Neurosci. 2014; 34(46): 15159-69.
28. Ashcroft FM. From molecule to malady. Nature. 2006; 440(7083): 440-7.
29. Catterall WA. Structure and function of voltagegated ion channels. Annu Rev Biochem. 1995; 64: 493-531.
30. McGivern JG. Advantages of voltage-gated ion channels as drug targets. Expert Opin Ther Targets. 2007; 11(3): 265-71.
31. Wulff H, Castle NA, Pardo LA. Voltage-gated potassium channels as therapeutic targets. Nat Rev Drug Discov. 2009; 8(12): 982-1001.
32. Lai HC, Jan LY. The distribution and targeting of neuronal voltage-gated ion channels. Nat Rev Neurosci. 2006; 7(7): 548-62.
33. Maljevic S, Lerche H. Potassium channels: a review of broadening therapeutic possibilities for neurological diseases. J Neurol. 2013; 260(9): 2201-11.
34. Stuhmer W, Ruppersberg JP, Schroter KH, Sakmann B, Stocker M, Giese KP, et al. Molecular basis of functional diversity of voltage-gated potassium channels in mammalian brain. EMBO J. 1989; 8(11): 3235-44.
35. Hibino H, Inanobe A, Furutani K, Murakami S, Findlay I, Kurachi Y. Inwardly rectifying potassium channels: their structure, function, and physiological roles. Physiol Rev. 2010; 90(1): 291-366.
36. Hoshi T, Zagotta WN, Aldrich RW. Biophysical and molecular mechanisms of Shaker potassium channel inactivation. Science. 1990; 250(4980): 533-8.
37. Xiong Q, Gao Z, Wang W, Li M. Activation of Kv7 (KCNQ) voltage-gated potassium channels by synthetic compounds. Trends Pharmacol Sci. 2008; 29(2): 99-107.
38. Wulff H, Pennington M. Targeting effector memory T-cells with Kv1.3 blockers. Current opinion in drug discovery & development. 2007; 10(4): 438-45.
39. Vacher H, Mohapatra DP, Trimmer JS. Localization and targeting of voltage-dependent ion channels in mammalian central neurons. Physiol Rev. 2008; 88(4): 1407-47.
40. Hansen HH, Ebbesen C, Mathiesen C, Weikop P, Ronn LC, Waroux O, et al. The KCNQ channel opener retigabine inhibits the activity of mesencephalic dopaminergic systems of the rat. The Journal of pharmacology and experimental therapeutics. 2006; 318(3): 1006-19.
41. Gutman GA, Chandy KG, Grissmer S, Lazdunski M, McKinnon D, Pardo LA, et al. International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels. Pharmacol Rev. 2005; 57(4): 473-508.
42. Brown DA, Passmore GM. Neural KCNQ (Kv7) channels. Br J Pharmacol. 2009; 156(8): 1185-95.
43. Goldschen-Ohm MP, Capes DL, Oelstrom KM, Chanda B. Multiple pore conformations driven by asynchronous movements of voltage sensors in a eukaryotic sodium channel. Nature communications. 2013; 4: 1350.
44. Smith-Maxwell CJ, Ledwell JL, Aldrich RW. Role of the S4 in cooperativity of voltagedependent potassium channel activation. The Journal of general physiology. 1998; 111(3): 399-420.
45. Armstrong CM, Bezanilla F. Currents related to movement of the gating particles of the sodium channels. Nature. 1973; 242(5398): 459-61.
46. Lacroix JJ, Campos FV, Frezza L, Bezanilla F. Molecular bases for the asynchronous activation of sodium and potassium channels required for nerve impulse generation. Neuron. 2013; 79(4): 651-7.
47. Heine M, Ciuraszkiewicz A, Voigt A, Heck J, Bikbaev A. Surface dynamics of voltage-gated ion channels. Channels. 2016; 10(4): 267-81.
48. Vacher H, Trimmer JS. Trafficking mechanisms underlying neuronal voltage-gated ion channel localization at the axon initial segment. Epilepsia. 2012; 53 Suppl 9: 21-31.
49. Goldin AL, Barchi RL, Caldwell JH, Hofmann F, Howe JR, Hunter JC, et al. Nomenclature of voltage-gated sodium channels. Neuron. 2000; 28(2): 365-8.
50. Brackenbury WJ, Isom LL. Na Channel beta Subunits: Overachievers of the Ion Channel Family. Frontiers in pharmacology. 2011; 2: 53.
51. O’Malley HA, Isom LL. Sodium channel beta subunits: emerging targets in channelopathies. Annual review of physiology. 2015; 77: 481-504.
52. Eijkelkamp N, Linley JE, Baker MD, Minett MS, Cregg R, Werdehausen R, et al. Neurological perspectives on voltage-gated sodium channels. Brain. 2012; 135(Pt 9): 2585-612.
53. Mantegazza M, Curia G, Biagini G, Ragsdale DS, Avoli M. Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders. Lancet Neurol. 2010; 9(4): 413-24.
54. Sun GC, Werkman TR, Battefeld A, Clare JJ, Wadman WJ. Carbamazepine and topiramate modulation of transient and persistent sodium currents studied in HEK293 cells expressing the Na(v)1.3 alpha-subunit. Epilepsia. 2007; 48(4): 774-82.
55. Large CH, Kalinichev M, Lucas A, Carignani C, Bradford A, Garbati N, et al. The relationship between sodium channel inhibition and anticonvulsant activity in a model of generalised seizure in the rat. Epilepsy Res. 2009; 85(1): 96-106.
56. Rush AM, Dib-Hajj SD, Waxman SG. Electrophysiological properties of two axonal sodium channels, Nav1.2 and Nav1.6, expressed in mouse spinal sensory neurones. The Journal of physiology. 2005; 564(Pt 3): 803-15.
57. Bagal SK, Brown AD, Cox PJ, Omoto K, Owen RM, Pryde DC, et al. Ion channels as therapeutic targets: a drug discovery perspective. J Med Chem. 2013; 56(3): 593-624.
58. Buraei Z, Yang J. Structure and function of the beta subunit of voltage-gated Ca(2)(+) channels. Biochim Biophys Acta. 2013; 1828(7): 1530-40.
59. Davies A, Hendrich J, Van Minh AT, Wratten J, Douglas L, Dolphin AC. Functional biology of the alpha(2)delta subunits of voltage-gated calcium channels. Trends Pharmacol Sci. 2007; 28(5): 220-8.
60. Guan F, Zhang T, Liu X, Han W, Lin H, Li L, et al. Evaluation of voltage-dependent calcium channel gamma gene families identified several novel potential susceptible genes to schizophrenia. Sci Rep. 2016; 6: 24914.
61. Simms BA, Zamponi GW. Neuronal voltagegated calcium channels: structure, function, and dysfunction. Neuron. 2014; 82(1): 24-45.
62. Weiergraber M, Stephani U, Kohling R. Voltagegated calcium channels in the etiopathogenesis and treatment of absence epilepsy. Brain research reviews. 2010; 62(2): 245-71.
63. Belardetti F, Ahn S, So K, Snutch TP, Phillips AG. Block of voltage-gated calcium channels stimulates dopamine efflux in rat mesocorticolimbic system. Neuropharmacology. 2009; 56(6-7): 984-93.
64. Barrallo-Gimeno A, Gradogna A, Zanardi I, Pusch M, Estevez R. Regulatory-auxiliary subunits of CLC chloride channel-transport proteins. The Journal of physiology. 2015; 593(18): 4111-27.
65. Steinke H. [William Harvey revisited]. Therapeutische Umschau Revue therapeutique. 2015; 72(7): 421-7.
66. Nys M, Kesters D, Ulens C. Structural insights into Cys-loop receptor function and ligand recognition. Biochem Pharmacol. 2013; 86(8): 1042-53.
67. Barry PH, Lynch JW. Ligand-gated channels. IEEE Trans Nanobioscience. 2005; 4(1): 70-80.
68. Galaz P, Barra R, Figueroa H, Mariqueo T. Advances in the pharmacology of lGICs auxiliary subunits. Pharmacol Res. 2015; 101: 65-73.
69. Lynagh T, Pless SA. Principles of agonist recognition in Cys-loop receptors. Front Physiol. 2014; 5: 160.
70. Steinlein OK. Genetic mechanisms that underlie epilepsy. Nat Rev Neurosci. 2004; 5(5): 400-8.
71. Shiang R, Ryan SG, Zhu YZ, Fielder TJ, Allen RJ, Fryer A, et al. Mutational analysis of familial and sporadic hyperekplexia. Ann Neurol. 1995; 38(1): 85-91.
72. Sine SM, Engel AG. Recent advances in Cysloop receptor structure and function. Nature. 2006; 440(7083): 448-55.
73. Krieger J, Bahar I, Greger IH. Structure, Dynamics, and Allosteric Potential of Ionotropic Glutamate Receptor N-Terminal Domains. Biophys J. 2015; 109(6): 1136-48.
74. Chohan MO, Iqbal K. From tau to toxicity: emerging roles of NMDA receptor in Alzheimer’s disease. J Alzheimers Dis. 2006; 10(1): 81-7.
75. Choi DW. Possible mechanisms limiting Nmethyl-D-aspartate receptor overactivation and the therapeutic efficacy of N-methyl-D-aspartate antagonists. Stroke. 1990; 21(11 Suppl): III20-2.
76. Rogawski MA. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res. 2006; 69(3): 273-94.
77. Black JA, Waxman SG. Phenytoin protects central axons in experimental autoimmune encephalomyelitis. J Neurol Sci. 2008; 274(1-2): 57-63.
78. Perucca E. A pharmacological and clinical review on topiramate, a new antiepileptic drug. Pharmacol Res. 1997; 35(4): 241-56.
79. Waszkielewicz AM, Gunia A, Sloczynska K, Marona H. Evaluation of anticonvulsants for possible use in neuropathic pain. Curr Med Chem. 2011; 18(28): 4344-58.
80. Brinkrolf P, Hahnenkamp K. Systemic lidocaine in surgical procedures: effects beyond sodium channel blockade. Curr Opin Anaesthesiol. 2014; 27(4): 420-5.
81. Patel R, Dickenson AH. Mechanisms of the gabapentinoids and alpha 2 delta-1 calcium channel subunit in neuropathic pain. Pharmacol Res Perspect. 2016; 4(2): e00205.
82. Zamponi GW, Striessnig J, Koschak A, Dolphin AC. The Physiology, Pathology, and Pharmacology of Voltage-Gated Calcium Channels and Their Future Therapeutic Potential. Pharmacol Rev. 2015; 67(4): 821-70.
83. Jiang R, Taly A, Grutter T. Moving through the gate in ATP-activated P2X receptors. Trends Biochem Sci. 2013; 38(1): 20-9.
84. Habermacher C, Dunning K, Chataigneau T, Grutter T. Molecular structure and function of P2X receptors. Neuropharmacology. 2016; 104: 18-30.
85. Burnstock G, Nistri A, Khakh BS, Giniatullin R. ATP-gated P2X receptors in health and disease. Front Cell Neurosci. 2014; 8: 204.
86. Shibuya I, Tanaka K, Hattori Y, Uezono Y, Harayama N, Noguchi J, et al. Evidence that multiple P2X purinoceptors are functionally expressed in rat supraoptic neurones. The Journal of physiology. 1999; 514 (Pt 2): 351-67.
87. Fabbretti E. ATP P2X3 receptors and neuronal sensitization. Front Cell Neurosci. 2013; 7: 236.
88. Tsuda M, Masuda T, Tozaki-Saitoh H, Inoue K. P2X4 receptors and neuropathic pain. Front Cell Neurosci. 2013; 7: 191.
89. Sperlagh B, Illes P. P2X7 receptor: an emerging target in central nervous system diseases. Trends Pharmacol Sci. 2014; 35(10): 537-47.
90. Nilius B, Owsianik G, Voets T, Peters JA. Transient receptor potential cation channels in disease. Physiol Rev. 2007; 87(1): 165-217.
91. Beech DJ. Characteristics of transient receptor potential canonical calcium-permeable channels and their relevance to vascular physiology and disease. Circ J. 2013; 77(3): 570-9.
92. Zheng F, Phelan KD. The role of canonical transient receptor potential channels in seizure and excitotoxicity. Cells. 2014; 3(2): 288-303.
93. Phelan KD, Shwe UT, Abramowitz J, Wu H, Rhee SW, Howell MD, et al. Canonical transient receptor channel 5 (TRPC5) and TRPC1/4 contribute to seizure and excitotoxicity by distinct cellular mechanisms. Molecular pharmacology. 2013; 83(2): 429-38.
94. Riccio A, Li Y, Tsvetkov E, Gapon S, Yao GL, Smith KS, et al. Decreased anxiety-like behavior and Galphaq/11-dependent responses in the amygdala of mice lacking TRPC4 channels. J Neurosci. 2014; 34(10): 3653-67.
95. Riccio A, Li Y, Moon J, Kim KS, Smith KS, Rudolph U, et al. Essential role for TRPC5 in amygdala function and fear-related behavior. Cell. 2009; 137(4): 761-72.
96. Westlund KN, Zhang LP, Ma F, Nesemeier R, Ruiz JC, Ostertag EM, et al. A rat knockout model implicates TRPC4 in visceral pain sensation. Neuroscience. 2014; 262: 165-75.
97. Kaneko Y, Szallasi A. TRP channels as therapeutic targets. Curr Top Med Chem. 2013; 13(3): 241-3.
98. Miller M, Shi J, Zhu Y, Kustov M, Tian JB, Stevens A, et al. Identification of ML204, a novel potent antagonist that selectively modulates native TRPC4/C5 ion channels. The Journal of biological chemistry. 2011; 286(38): 33436-46.
99. Richter JM, Schaefer M, Hill K. Clemizole hydrochloride is a novel and potent inhibitor of transient receptor potential channel TRPC5. Molecular pharmacology. 2014; 86(5): 514-21.
100. Rohacs T. Phosphoinositide regulation of TRP channels. Handbook of experimental pharmacology. 2014; 223: 1143-76.
101. DiFrancesco JC, DiFrancesco D. Dysfunctional HCN ion channels in neurological diseases. Front Cell Neurosci. 2015; 6: 174.
102. Podda MV, Grassi C. New perspectives in cyclic nucleotide-mediated functions in the CNS: the emerging role of cyclic nucleotide-gated (CNG) channels. Pflugers Arch. 2014; 466(7): 1241-57.
103. Hofmann F, Biel M, Kaupp UB. International Union of Pharmacology. LI. Nomenclature and structure-function relationships of cyclic nucleotide-regulated channels. Pharmacol Rev. 2005; 57(4): 455-62.
104. Trudeau MC, Zagotta WN. An intersubunit interaction regulates trafficking of rod cyclic nucleotide-gated channels and is disrupted in an inherited form of blindness. Neuron. 2002; 34(2): 197-207.
105. Kohl S, Baumann B, Broghammer M, Jagle H, Sieving P, Kellner U, et al. Mutations in the CNGB3 gene encoding the beta-subunit of the cone photoreceptor cGMP-gated channel are responsible for achromatopsia (ACHM3) linked to chromosome 8q21. Hum Mol Genet. 2000; 9(14): 2107-16.
106. Roper J, Ashcroft FM. Metabolic inhibition and low internal ATP activate K-ATP channels in rat dopaminergic substantia nigra neurones. Pflugers Arch. 1995; 430(1): 44-54.
107. Stanford IM, Lacey MG. Electrophysiological investigation of adenosine trisphosphate sensitive potassium channels in the rat substantia nigra pars reticulata. Neuroscience. 1996; 74(2): 499-509.
108. Ashford ML, Boden PR, Treherne JM. Tolbutamide excites rat glucoreceptive ventromedial hypothalamic neurones by indirect inhibition of ATP-K+ channels. Br J Pharmacol. 1990; 101(3): 531-40.
109. Chien M, Morozova I, Shi S, Sheng H, Chen J, Gomez SM, et al. The genomic sequence of the accidental pathogen Legionella pneumophila. Science. 2004; 305(5692): 1966-8.
110. Yamada K, Inagaki N. ATP-sensitive K(+) channels in the brain: sensors of hypoxic conditions. News Physiol Sci. 2002; 17: 127-30.
111. Rubaiy HN. Ion Channels as Drug Target in the Clinic. Austin Internal Medicine. 2016; 1(2): 1009.
112. Coste B, Mathur J, Schmidt M, Earley TJ, Ranade S, Petrus MJ, et al. Piezo1 and Piezo2 are essential components of distinct mechanically activated cation channels. Science. 2010; 330(6000): 55-60.
113. Kamajaya A, Kaiser JT, Lee J, Reid M, Rees DC. The structure of a conserved piezo channel domain reveals a topologically distinct beta sandwich fold. Structure. 2014; 22(10): 1520-7.
114. Li J, Hou B, Tumova S, Muraki K, Bruns A, Ludlow MJ, et al. Piezo1 integration of vascular architecture with physiological force. Nature. 2014; 515(7526): 279-82.
115. Coste B, Houge G, Murray MF, Stitziel N, Bandell M, Giovanni MA, et al. Gain-of-function mutations in the mechanically activated ion channel PIEZO2 cause a subtype of Distal Arthrogryposis. Proc Natl Acad Sci U S A. 2013; 110(12): 4667-72.
116. Linsdell P. Functional architecture of the CFTR chloride channel. Mol Membr Biol. 2014; 31(1): 1-16.
117. Wang W, El Hiani Y, Rubaiy HN, Linsdell P. Relative contribution of different transmembrane segments to the CFTR chloride channel pore. Pflugers Arch. 2014; 466(3): 477-90.
118. Cho H, Yang YD, Lee J, Lee B, Kim T, Jang Y, et al. The calcium-activated chloride channel anoctamin 1 acts as a heat sensor in nociceptive neurons. Nat Neurosci. 2012; 15(7): 1015-21.
119. Dib-Hajj SD, Yang Y, Waxman SG. Genetics and molecular pathophysiology of Na(v)1.7- related pain syndromes. Adv Genet. 2008; 63: 85-110.
120. Maingret F, Lauritzen I, Patel AJ, Heurteaux C, Reyes R, Lesage F, et al. TREK-1 is a heatactivated background K(+) channel. EMBO J. 2000; 19(11): 2483-91.
121. Vandenberg JI, Varghese A, Lu Y, Bursill JA, Mahaut-Smith MP, Huang CL. Temperature dependence of human ether-a-go-go-related gene K+ currents. Am J Physiol Cell Physiol. 2006; 291(1): C165-75.
122. Krishtal O. The ASICs: signaling molecules? Modulators?. Trends Neurosci. 2003; 26(9): 477-83.
123. Wemmie JA, Askwith CC, Lamani E, Cassell MD, Freeman JH, Jr., Welsh MJ. Acid-sensing ion channel 1 is localized in brain regions with high synaptic density and contributes to fear conditioning. J Neurosci. 2003; 23(13): 5496-502.
124. Wemmie JA, Coryell MW, Askwith CC, Lamani E, Leonard AS, Sigmund CD, et al. Overexpression of acid-sensing ion channel 1a in transgenic mice increases acquired fear-related behavior. Proc Natl Acad Sci U S A. 2004; 101(10): 3621-6.
125. Ziemann AE, Allen JE, Dahdaleh NS, Drebot, II, Coryell MW, Wunsch AM, et al. The amygdala is a chemosensor that detects carbon dioxide and acidosis to elicit fear behavior. Cell. 2009; 139(5): 1012-21.
126. Ziemann AE, Schnizler MK, Albert GW, Severson MA, Howard MA, 3rd, Welsh MJ, et al. Seizure termination by acidosis depends on ASIC1a. Nat Neurosci. 2008; 11(7): 816-22.
127. Luszczki JJ, Sawicka KM, Kozinska J, Dudra-Jastrzebska M, Czuczwar SJ. Amiloride enhances the anticonvulsant action of various antiepileptic drugs in the mouse maximal electroshock seizure model. Journal of neural transmission. 2009; 116(1): 57-66.
128. Lv RJ, He JS, Fu YH, Zhang YQ, Shao XQ, Wu LW, et al. ASIC1a polymorphism is associated with temporal lobe epilepsy. Epilepsy Res. 2011; 96(1-2): 74-80.
129. Kyle DJ, Ilyin VI. Sodium channel blockers. J Med Chem. 2007; 50(11): 2583-8.
130. Defranchi E, Novellino A, Whelan M, Vogel S, Ramirez T, van Ravenzwaay B, et al. Feasibility Assessment of Micro-Electrode Chip Assay as a Method of Detecting Neurotoxicity in vitro. Frontiers in neuroengineering. 2011; 4: 6.